These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 37873943

  • 1. Serum Testosterone and Dihydrotestosterone and Incidence and Progression of Lower Urinary Tract Symptoms: Results From the REDUCE Study.
    Daniels JP, Mirocha J, Adjei M, Moreira D, Freedland SJ.
    J Urol; 2024 Jan; 211(1):101-110. PubMed ID: 37873943
    [Abstract] [Full Text] [Related]

  • 2. Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
    Kramer JJ, Gu L, Moreira D, Andriole G, Csizmadi I, Freedland SJ.
    J Urol; 2022 Feb; 207(2):417-423. PubMed ID: 34544265
    [Abstract] [Full Text] [Related]

  • 3. Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction.
    Shigehara K, Miyagi T, Nakashima T, Izumi K, Kitagawa Y, Mizokami A, Koh E, Shimamura M, Namiki M.
    Aging Male; 2016 Jun; 19(2):128-33. PubMed ID: 26890877
    [Abstract] [Full Text] [Related]

  • 4. Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study.
    Feng T, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ.
    Int J Urol; 2017 Feb; 24(2):151-156. PubMed ID: 28004415
    [Abstract] [Full Text] [Related]

  • 5. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
    Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ.
    Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
    [Abstract] [Full Text] [Related]

  • 6. Smoking and lower urinary tract symptoms in Reduction by Dutasteride of Prostate Cancer Events Trial.
    Kramer JJ, Gu L, Moreira D, Andriole G, Freedland SJ, Csizmadi I.
    Prostate; 2023 Jul; 83(10):990-997. PubMed ID: 37070723
    [Abstract] [Full Text] [Related]

  • 7. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
    Page ST, Hirano L, Gilchriest J, Dighe M, Amory JK, Marck BT, Matsumoto AM.
    J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
    [Abstract] [Full Text] [Related]

  • 8. Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention.
    Nickel JC, Roehrborn CG, Castro-Santamaria R, Freedland SJ, Moreira DM.
    J Urol; 2016 Nov; 196(5):1493-1498. PubMed ID: 27378134
    [Abstract] [Full Text] [Related]

  • 9. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
    Simon RM, Howard LE, Moreira DM, Roehrborn C, Vidal AC, Castro-Santamaria R, Freedland SJ.
    Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
    [Abstract] [Full Text] [Related]

  • 10. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.
    Toren P, Margel D, Kulkarni G, Finelli A, Zlotta A, Fleshner N.
    BMJ; 2013 Apr 15; 346():f2109. PubMed ID: 23587564
    [Abstract] [Full Text] [Related]

  • 11. Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE.
    Simon RM, Howard LE, Moreira DM, Roehrborn C, Vidal A, Castro-Santamaria R, Freedland SJ.
    J Urol; 2017 Sep 15; 198(3):650-656. PubMed ID: 28428110
    [Abstract] [Full Text] [Related]

  • 12. Dutasteride Improves Nocturia but Does Not Lead to Better Sleep: Results from the REDUCE Clinical Trial.
    Kuhlmann PK, Fischer SC, Howard LE, Moreira DM, Andriole GL, Hopp ML, Roehrborn CG, Bliwise DL, Freedland SJ.
    J Urol; 2021 Jun 15; 205(6):1733-1739. PubMed ID: 33605791
    [Abstract] [Full Text] [Related]

  • 13. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R.
    Urology; 2008 Oct 15; 72(4):808-12. PubMed ID: 18718641
    [Abstract] [Full Text] [Related]

  • 14. Sleep Problems are Associated with Development and Progression of Lower Urinary Tract Symptoms: Results from REDUCE.
    Branche BL, Howard LE, Moreira DM, Roehrborn C, Castro-Santamaria R, Andriole GL, Hopp ML, Freedland SJ.
    J Urol; 2018 Feb 15; 199(2):536-542. PubMed ID: 28870861
    [Abstract] [Full Text] [Related]

  • 15. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
    Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R.
    Prostate Cancer Prostatic Dis; 2007 Feb 15; 10(2):149-54. PubMed ID: 17189955
    [Abstract] [Full Text] [Related]

  • 16. Understanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression.
    Gravas S, Palacios-Moreno JM, Thompson D, Concas F, Kamola PJ, Roehrborn CG, Oelke M, Kattan MW, Averbeck MA, Manyak M, Cortés V, Lulic Z.
    Eur Urol Focus; 2023 Jan 15; 9(1):178-187. PubMed ID: 35985933
    [Abstract] [Full Text] [Related]

  • 17. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
    Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S.
    J Clin Endocrinol Metab; 2004 May 15; 89(5):2179-84. PubMed ID: 15126539
    [Abstract] [Full Text] [Related]

  • 18. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
    O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K.
    BJU Int; 2003 Aug 15; 92(3):262-6. PubMed ID: 12887480
    [Abstract] [Full Text] [Related]

  • 19. Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.
    Kacker R, Harisaran V, Given L, Miner M, Rittmaster R, Morgentaler A.
    Andrologia; 2015 Mar 15; 47(2):148-52. PubMed ID: 24499051
    [Abstract] [Full Text] [Related]

  • 20. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G, Rittmaster RS, Klocker H.
    World J Urol; 2002 Apr 15; 19(6):413-25. PubMed ID: 12022710
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.